Effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19:A retrospective cohort study  

作　　者：Bin Xiong Li-Min He Yuan-Yuan Qin Hu Du Zhu Zhan Yi-Hong Zhou Yao-Kai Chen An Zhang 

机构地区：[1]Department of Critical Care Medicine,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China [2]Department of Cardiology,The First Branch of The First Affiliated Hospital,Chongqing Medical University,Chongqing 400015,China [3]Division of Infectious Diseases,Chongqing Public Health Medical Center,Chongqing 400036,China

出　　处：《World Journal of Clinical Cases》2021年第15期3546-3558,共13页世界临床病例杂志

摘　　要：BACKGROUND The effectiveness of adjunctive corticosteroid use in patients with coronavirus disease 2019(COVID-19)remains inconclusive.AIM To investigate the effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19.METHODS We conducted a retrospective analysis of the difference in several outcomes between patients with severe COVID-19 who received corticosteroid therapy(the corticosteroid group)and patients with severe COVID-19 who did not receive corticosteroid therapy(the non-corticosteroid group).RESULTS Seventy-five patients were included in this study.Of these,47 patients were in the corticosteroid group and 28 patients were in the non-corticosteroid group.There were no differences between the two groups in the total length of hospital stay,the length of intensive care unit stay,high-flow oxygen days,non-invasive ventilator days,invasive ventilation days,and mortality rate.Total lesion volume ratio,consolidation volume ratio and ground-glass opacity volume ratio in the corticosteroid group decreased significantly on day 14,while those in the noncorticosteroid group did not show a significant decrease.CONCLUSION Our results show that adjunctive corticosteroid use did not significantly improveclinical outcomes in severe COVID-19 patients,but might promote the absorptionof pulmonary lesions.Larger multicenter randomized controlled studies may beneeded to confirm this.

关 键 词：COVID-19 CORTICOSTEROID SARS-CoV-2 OUTCOMES 

分 类 号：R563.1[医药卫生—呼吸系统]